Research-Grade Peptides | 99%+ Purity Verified | US Delivery 2–5 Days
Save 5% with Crypto
SaiyanMed

Your Cart

No products in the cart.

AOD-9604 Structure and Sequence | Research Analysis of the hGH 177-191 Fragment

IMPORTANT — RESEARCH USE ONLY. This article is for qualified laboratory researchers.

It is not a home-use guide. Any information about solvents, concentration, storage, reduction, or testing applies only to controlled laboratory work and must not be used for human or veterinary administration, injection, consumption, cosmetic use, or personal use.

AOD-9604 is a synthetic 16-amino-acid intramolecular disulfide-bridged peptide containing a cystine-constrained loop between Cys7 and Cys14. It is not head-to-tail cyclized.

AOD-9604 Structure and Sequence | Research Analysis of the hGH 177-191 Fragment

The peptide contains the human growth hormone (hGH) 177–191 sequence with an additional tyrosine at the N-terminus. PubChem (CID 71300630) records the neutral oxidized peptide under CAS 221231-10-3, with the formula C78H123N23O23S2, an average molecular weight of 1815.1 g/mol, and a monoisotopic exact mass of 1813.8604 Da.

Computed physicochemical properties include an XLogP3-AA of −4.8, a topological polar surface area of 815 Ų, and 28 hydrogen bond donors and 28 hydrogen bond acceptors. PubChem also records UNII 7UP768IP4M and DrugBank DB06388.

The same 16-residue sequence is reported in a peer-reviewed analytical study of AOD-9604 and its in vitro metabolites.[1][2]

Parent hGH Fragment

The canonical GH1 precursor (UniProt P01241) contains 217 amino acids, including a 26-residue signal peptide. After signal-peptide removal, the principal mature 22-kDa hGH form contains 191 amino acids.

Numbering such as hGH 177–191 refers to this mature 191-residue hormone. The final 15 residues of mature hGH are LRIVQCRSVEGSCGF, corresponding to hGH 177–191.

Full-length hGH also contains a disulfide bond between Cys182 and Cys189 (positions 7 and 14 within the 177–191 fragment).[3]

Full-length hGH is a four-helix protein, and its receptor (PDB 3HHR) binds to a surface formed by several parts of the protein. The short 177–191 fragment does not contain the complete receptor-binding surface of full-length hGH.[4]

The unmodified hGH 177–191 fragment (15 residues, sometimes referenced as AOD-9401) was studied in isolated rat epididymal fat pads. The 1993 study by Wu and Ng reported an antilipogenic effect—inhibition of lipid synthesis—comparable to that of intact hGH in the tested model.

No significant lipolytic effect was detected by glycerol-release measurement in the peptide-treated preparations under the stated conditions. These results support the view that a C-terminal region of hGH can influence lipid metabolism at the level of lipogenesis, but they do not establish a general lipolytic mechanism for the fragment.

The findings apply only to the stated cell model and should not be presented as evidence for human or veterinary use.[5]

AOD-9604 Sequence

AOD-9604 adds one tyrosine before the leucine at the start of hGH 177–191. The leucine is not replaced.

The full sequence is:[1][2]

Y-L-R-I-V-Q-C-R-S-V-E-G-S-C-G-F

One-letter code: YLRIVQCRSVEGSCGF

Position Code Amino acid Source
1 Y Tyrosine Added N-terminal residue
2 L Leucine hGH 177
3 R Arginine hGH 178
4 I Isoleucine hGH 179
5 V Valine hGH 180
6 Q Glutamine hGH 181
7 C Cysteine hGH 182; bonded to Cys14
8 R Arginine hGH 183
9 S Serine hGH 184
10 V Valine hGH 185
11 E Glutamic acid hGH 186
12 G Glycine hGH 187
13 S Serine hGH 188
14 C Cysteine hGH 189; bonded to Cys7
15 G Glycine hGH 190
16 F Phenylalanine hGH 191

Disulfide Bond and Shape

Cys7 and Cys14 form one internal disulfide bond. Six amino acids sit between the two cysteines, and the full disulfide-bridged section is the eight-residue sequence CRSVEGSC.

Forming the bond removes two hydrogen atoms from the reduced peptide. Reducing the bond therefore increases the neutral mass by about 2.0157 Da.

The disulfide bond limits movement around this part of the peptide, but it does not prove that the isolated peptide always has one fixed three-dimensional shape. Its shape can change with pH, solvent, salt form, concentration, and temperature.

Claims about a specific beta-hairpin, NMR structure, circular-dichroism pattern, or aggregation limit require direct AOD-9604 test data.

Key Chemical Data

Property Value
CAS number 221231-10-3
Sequence YLRIVQCRSVEGSCGF
Amino-acid count 16
Molecular formula C78H123N23O23S2
Average molecular weight 1815.1 g/mol
Monoisotopic exact mass (neutral) 1813.8604 Da
Calculated [M+H]+ m/z 1814.8676
Calculated [M+2H]2+ m/z 907.9375
Calculated [M+3H]3+ m/z 605.6274
Disulfide bond Cys7–Cys14
N-terminus Free amino group on Tyr1 in the neutral structure
C-terminus Free carboxyl group on Phe16 in the neutral structure

These values describe the neutral oxidized peptide recorded by PubChem.[1]

A supplied batch may also contain a salt such as acetate (PubChem records AOD9604 acetate as a synonym) or trifluoroacetate, water, or small amounts of process-related material. For that reason, total powder weight is not automatically the same as net peptide content.

What Published Laboratory Studies Show

The unmodified 15-residue hGH 177–191 fragment, sometimes called AOD-9401, was studied in isolated rat fat cells and in obese Zucker rats. The studies reported changes in selected lipid-metabolism and body-weight-gain measurements under their stated laboratory conditions.[5][6]

AOD-9604 was later studied in rodent models. Those papers reported changes in weight gain, fat mass, fat oxidation, and related laboratory endpoints under specific experimental protocols.[7][8]

In one cell assay reported in the mouse-study literature, AOD-9604 did not compete with hGH for receptor binding and did not trigger proliferation in the tested hGH-receptor-transfected cells.[9] This result is limited to that assay and does not prove that all receptor or off-target effects are absent.

These preclinical findings did not establish clinical weight-loss efficacy. A subsequent Phase IIb human obesity study did not meet its primary endpoint, and development for obesity was discontinued.

The animal results should therefore not be presented as evidence of human effectiveness or as a predictor of clinical outcomes.

An in vitro study of AOD-9604 in serum and urine found several shortened peptide products. The fragment CRSVEGSCG was more stable in the tested serum system than the parent peptide and the other measured metabolites.[2]

This finding does not support a general claim that the full peptide is long-lived in every biological or laboratory system.

Solubility, Preparation, and Storage

Laboratory use only. This section gives general quality-control guidance.

It is not a dosing, injection, or personal-use procedure.

There is no single solvent, stock concentration, or solubility value that can be applied to every AOD-9604 batch. Results may change with the salt form, purity, pH, temperature, concentration, and buffer.

For laboratory method development, test a small amount first and record the solvent, pH, temperature, mixing method, concentration, appearance, and recovery. Do not assume that a method used for one batch or analytical system will work unchanged in another.

The analytical method should be shown to work for its intended purpose.[10]

Haze, particles, or precipitation may indicate poor solubility, aggregation, contamination, or loss of stability. They should be investigated rather than described as automatically normal.

Follow the batch label and Certificate of Analysis for storage. When a batch is specified for storage at −20 °C, keep the dry material sealed, dry, and protected from light.

Allow the sealed container to equilibrate to room temperature before opening where appropriate, to reduce moisture condensation. Do not state a fixed shelf life or solution-stability period unless it is supported by batch-specific stability data.

HPLC, Mass Spectrometry, and COA Checks

COA limitation: A Certificate of Analysis describes laboratory quality tests for a specific batch. It does not prove sterility, human or veterinary safety, clinical effectiveness, or approval for administration.

Mass Spectrometry

The calculated neutral monoisotopic mass of oxidized AOD-9604 is 1813.8604 Da, and the calculated singly protonated ion is m/z 1814.8676. In electrospray ionization, multiple charge states are commonly observed; additional expected ions include [M+2H]2+ at m/z 907.9375 and [M+3H]3+ at m/z 605.6274.

The covalent peptide mass does not change with the counterion—acetate or trifluoroacetate salts affect total powder mass and composition, and may introduce salt-associated ions in the spectrum, but the theoretical mass of the parent AOD-9604 ion remains the same. Observed values may shift because of charge state, isotope assignment, sodium or other adducts, calibration, and unresolved salt-associated species.

An intact mass that matches the expected value supports identity, but it does not by itself prove the Cys7–Cys14 connection. When the disulfide position must be confirmed, a laboratory may need reduced and non-reduced comparisons, alkylation, peptide mapping, or suitable tandem mass spectrometry.

If one method is not specific enough, a second method should be used.[10]

HPLC Purity

HPLC area purity depends on the column, mobile phase, gradient, wavelength, temperature, integration settings, and detector response. A result from one method cannot be treated as identical to a result from a different method.

HPLC area percentage is also not the same as net peptide content. Water, counterions, residual solvents, inorganic salts, and compounds with weak UV response may not be represented in the same way.

Identity should not be based only on retention time.[11]

Useful COA Information

A clear research-peptide COA should list:

  • the product name
  • sequence
  • batch number
  • salt form
  • identity test
  • observed mass
  • HPLC method and result
  • storage condition
  • and test date

For quantitative work, net peptide content should be stated with the calculation basis clearly indicated (e.g., as-is, anhydrous, counterion-free, or peptide-equivalent basis). Water content (typically by Karl Fischer titration) and residual solvents should be included when they matter for quantitative calculations or are relevant to the manufacturing process.

A single HPLC purity number is not a complete description of the material. ICH Q3C(R8) gives general principles for classifying and controlling residual solvents based on risk, but it is not a product-specific specification for AOD-9604.[12]

These ICH documents are cited for general analytical and specification-setting principles. They do not establish a product-specific or legally mandatory specification for an AOD-9604 research-use-only material.

Research References

  1. PubChem. Aod-9604, CID 71300630. National Center for Biotechnology Information, U.S. National Library of Medicine. Average MW 1815.1 g/mol, monoisotopic mass 1813.8604 Da, UNII 7UP768IP4M. https://pubchem.ncbi.nlm.nih.gov/compound/Aod-9604
  2. Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. Detection and in vitro metabolism of AOD9604. Drug Testing and Analysis. 2015;7(1):31–38. PMID: 25208511. https://pubmed.ncbi.nlm.nih.gov/25208511/
  3. UniProt Consortium. Somatotropin (GH1), Homo sapiens, UniProtKB P01241. 217-aa precursor with 26-residue signal peptide; mature 191-aa hormone. https://www.uniprot.org/uniprotkb/P01241/entry
  4. de Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science. 1992;255(5042):306–312. RCSB PDB: 3HHR. https://www.rcsb.org/structure/3HHR
  5. Wu Z, Ng FM. Antilipogenic action of synthetic C-terminal sequence 177–191 of human growth hormone. Biochemistry and Molecular Biology International. 1993;30(1):187–196. PMID: 8358331. Antilipogenic effect; no significant lipolytic effect by glycerol-release measurement. https://pubmed.ncbi.nlm.nih.gov/8358331/
  6. Ng FM, Jiang WJ, Gianello R, Pitt S, Roupas P. Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats. Journal of Molecular Endocrinology. 2000;25(3):287–298. PMID: 11116208. https://pubmed.ncbi.nlm.nih.gov/11116208/
  7. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research. 2000;53(6):274–278. PMID: 11146367. https://pubmed.ncbi.nlm.nih.gov/11146367/
  8. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182–5189. PMID: 11713213. https://pubmed.ncbi.nlm.nih.gov/11713213/
  9. Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. International Journal of Obesity and Related Metabolic Disorders. 2001;25(10):1442–1449. PMID: 11673763. AOD-9604 did not compete with hGH for receptor binding; did not trigger proliferation in hGH-receptor-transfected cells. https://pubmed.ncbi.nlm.nih.gov/11673763/
  10. International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures. https://database.ich.org/sites/default/files/ICH_Q2%28R2%29_Guideline_2023_1130.pdf
  11. International Council for Harmonisation. ICH Q6A: Specifications—Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. https://database.ich.org/sites/default/files/Q6A%20Guideline.pdf
  12. International Council for Harmonisation. ICH Q3C(R8): Impurities—Guideline for Residual Solvents. https://database.ich.org/sites/default/files/ICH_Q3C-R8_Guideline_Step4_2021_0422_1.pdf

Research Use Only Disclaimer

Research Use Only: The AOD-9604 material described on this page is intended solely for qualified laboratory research and is not approved for human or veterinary administration. This article provides general scientific and analytical information only.

It does not provide a validated experimental protocol, medical advice, veterinary advice, dosing instructions, or authorization for in vivo work. Any animal research must be conducted under applicable institutional approvals and legal requirements.